Best anaesthetic drug strategy for morbidly obese patients

Current Opinion in Anaesthesiology

Volumn 29, Issue 1, 2016, Pages 119-128

  De Baerdemaeker, Luc ^a   Margarson, Michael ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b ST RICHARD S HOSPITAL   (United Kingdom)

Author keywords

dosing scalars; enhanced recovery after bariatric surgery; multimodal analgesia

Indexed keywords

ANALGESIC AGENT; ANESTHETIC AGENT; ANTIEMETIC AGENT; CLONIDINE; DEXAMETHASONE; DEXMEDETOMIDINE; KETAMINE; LIDOCAINE; MAGNESIUM; NEUROMUSCULAR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; TAPENTADOL; TRAMADOL; VOLATILE AGENT;

ALLOMETRY; ANALGESIA; ANESTHESIA; ARTICLE; BARIATRIC SURGERY; DRUG SAFETY; HUMAN; INCIDENCE; INTENSIVE CARE; MORBID OBESITY; POSTOPERATIVE NAUSEA; PREMEDICATION; PRIORITY JOURNAL; SLEEP DISORDERED BREATHING; THROMBOSIS PREVENTION; TREATMENT OUTCOME; COMPLICATION; OBESITY, MORBID; PROCEDURES;

ANESTHESIA; ANESTHETICS; BARIATRIC SURGERY; HUMANS; OBESITY, MORBID;

EID: 84952714513     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0000000000000286     Document Type: Article

References (72)

1. Fearon KC, Ljungqvist O, Von Meyenfeldt M. Enhanced recovery after surgery: a consensus review of clinical care for patients undergoing colonic resection. Clin Nutr 2005; 24:466-477.
2. Mahajan V, Hashmi J, Singh R, et al. Comparative evaluation of gastric pH and volume in morbidly obese and lean patients undergoing elective surgery and effect of aspiration prophylaxis. J Clin Anesth 2015; 27:396-400.
3. Freid EB. The rapid sequence induction revisited: obesity and sleep apnea syndrome. Anesthesiol Clin North Am 2005; 23:551-564.
4. Perlas A, Chan VWS, Lupu CM, et al. Ultrasound assessment of gastric content and volume. Anesthesiology 2009; 111:82-89.
5. Koolwijk J, Schors M, el Bouazati S, Noordergraaf GJ. Airway management concerns in patient with gastric banding procedures. BMJ Case Rep 2013. [Epub ahead of print]. doi:10.1136/bcr-2013-201009.
6. Jean J, Compè re V, Fourdrinier V, et al. The risk of pulmonary aspiration in patients after weight loss due to bariatric surgery. Anesth Analg 2008; 107:1257-1259.
7. Lemanu DP, Srinivasa S, Singh PP, et al. Optimizing perioperative care in bariatric surgery patients. Obes Surg 2012; 22:979-990.
8. Awad S, Carter S, Purkayastha S, et al. Enhanced recovery after bariatric surgery (ERABS): clinical outcomes from a tertiary referral bariatric centre. Obes Surg 2014; 24:753-758.
9. Lemanu DP, Singh PP, Berridge K, et al. Randomized clinical trial of enhanced recovery versus standard care after laparoscopic sleeve gastrectomy. Br J Surg 2013; 100:482-489.
10. Galloro G, Sivero L, Magno L, et al. New technique for endoscopic removal of intragastric balloon placed for treatment of morbid obesity. Obes Surg 2007; 17:658-662.
11. Supariwala A, Makani H, Kahan J, et al. Feasibility and prognostic value of stress echocardiography in obese, morbidly obese, and super obese patients referred for bariatric surgery. Echocardiography 2014; 31:879-885.
12. Garimella S, Longaker RA, Stoddard MF. Safety of transesophageal echocardiography in patients who are obese. J Am Soc Echocardiogr 2002; 15:1396-1400.
13. Brill MJE, van Rongen A, Houwink API, et al. Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers. Clin Pharmacokinet 2014; 53:931-941.
14. Sollazzi L, Modesti C, Vitale F, et al. Preinductive use of clonidine and ketamine improves recovery and reduces postoperative pain after bariatric surgery. Surg Obes Relat Dis 2009; 5:67-71.
15. Jayaraman L, Sinha A, Punhani D. A comparative study to evaluate the effect of intranasal dexmedetomidine versus oral alprazolam as a premedication agent in morbidly obese patients undergoing bariatric surgery. J Anaesthesiol Clin Pharmacol 2013; 29:179-182.
16. Khalili G, Janghorbani M, Saryazdi H, Emaminejad A. Effect of preemptive and preventive acetaminophen on postoperative pain score: a randomized, double-blind trial of patients undergoing lower extremity surgery. J Clin Anesth 2013; 25:188-192.
17. Kamelgard JI, Kim KA, Atlas G. Combined preemptive and preventive analgesia in morbidly obese patients undergoing open gastric bypass: a pilot study. Surg Obes Relat Dis 2005; 1:12-16.
18. Durmus M, Buta K, Saricicek V, et al. The postoperative analgesic effects of a combination of gabapentin and paracetamol in patients undergoing abdominal hysterectomy: a randomized clinical trial. Acta Anaesthesiol Scand 2007; 51:299-304.
19. Hassani V, Pazouki A, Nikoubakht N, et al. The effect of gabapentin on reducing pain after laparoscopic gastric bypass surgery in patients with morbid obesity: a randomized clinical trial. Anesthesiol pain Med 2015; 5:e22372.
20. Cabrera Schulmeyer MC, de la Maza J, Ovalle C, et al. Analgesic effects of a single preoperative dose of pregabalin after laparoscopic sleeve gastrectomy. Obes Surg 2010; 20:1678-1681.
21. Froehling DA, Daniels PR, Mauck KF, et al. Incidence of venous thromboembolism after bariatric surgery: a population-based cohort study. Obes Surg 2013; 23:1874-1879.
22. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl):381S-453S.
23. Wang T-F, Milligan PE, Wong Ca, et al. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thromb Haemost 2014; 111:88-93.
24. Gerlach AT, Folino J, Morris BN, et al. Comparison of heparin dosing based on actual body weight in nonobese, obese and morbidly obese critically ill patients. Int J Crit Illn Inj Sci 2013; 3:195-199.
25. Celik F, Huitema ADR, Hooijberg JH, et al. Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak antixa levels. Obes Surg 2015; 25:628-634.
26. Nutescu E, Spinler S, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009; 43:1064-1083.
27. Freeman AL, Pendleton RC, Rondina MT. Prevention of venous thromboembolism in obesity. Expert Rev Cardiovasc Ther 2010; 8:1711-1721.
28. Rondina MT, Wheeler M, Rodgers GM, et al. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. Thromb Res 2010; 125:220-223.
29. Diepstraten J, Janssen EJH, Hackeng CM, et al. Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and nonobese patients using anti-Xa levels as endpoint. Eur J Clin Pharmacol 2015; 71:25-34.
30. Patel JP, Roberts LN, Arya R. Anticoagulating obese patients in the modern era. Br J Haematol 2011; 155:137-149.
31. Sudré ECM, de Batista PR, Castiglia YMM. Longer immediate recovery time after anesthesia increases risk of respiratory complications after laparotomy for bariatric surgery: a randomized clinical trial and a cohort study. Obes Surg 2015; 25:2205-2212.
32. Stelfox HT, Ahmed SB, Ribeiro Ra, et al. Hemodynamic monitoring in obese patients: the impact of body mass index on cardiac output and stroke volume. Crit Care Med 2006; 34:1243-1246.
33. Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44:1051-1065.
34. De Baerdemaeker L, Mortier E, Struys M. CEECAP 2001; 4:152-155.
35. Eleveld DJ, Proost JH, Absalom AR; Struys MMRF. Obesity and allometric scaling of pharmacokinetics. Clin Pharmacokinet 2011; 50:751-753.
36. Eger EI 2nd. New inhaled anesthetics. Anesthesiology 1994; 80:906-922.
37. Casati A, Marchetti C, Spreafico E, Mamo D. Effects of obesity on wash-in and wash-out kinetics of sevoflurane. Eur J Anaesthesiol 2004; 21:243-245.
38. Lemmens HJM, Saidman LJ, Eger EI, Laster MJ. Obesity modestly affects inhaled anesthetic kinetics in humans. Anesth Analg 2008; 107:1864-1870.
39. Macario A, Dexter F, Lubarsky D. Meta-analysis of trials comparing postoperative recovery after anesthesia with sevoflurane or desflurane. Am J Health Syst Pharm 2005; 62:63-68.
40. Vallejo MC, Sah N, Phelps AL, et al. Desflurane versus sevoflurane for laparoscopic gastroplasty in morbidly obese patients. J Clin Anesth 2007; 19:3-8.
41. Strum EM, Szenohradszki J, Kaufman Wa, et al. Emergence and recovery characteristics of desflurane versus sevoflurane in morbidly obese adult surgical patients: a prospective, randomized study. Anesth Analg 2004; 99:1848-1853.
42. De Corte W, Delrue H, Vanfleteren LJJ, et al. Randomized clinical trial on the influence of anaesthesia protocol on intestinal motility during laparoscopic surgery requiring small bowel anastomosis. Br J Surg 2012; 99:1524-1529.
43. Brodsky JB, Lemmens HJM, Collins JS, et al. Nitrous oxide and laparoscopic bariatric surgery. Obes Surg 2005; 15:494-496.
44. Peyton PJ, Chao I, Weinberg L, et al. Nitrous oxide diffusion and the second gas effect on emergence from anesthesia. Anesthesiology 2011; 114:596-602.
45. Chan MT, Wan ACM, Gin T, et al. Chronic postsurgical pain after nitrous oxide anesthesia. Pain 2011; 152:2514-2520.
46. Leeson S, Roberson RS, Philip JH. Hypoventilation after inhaled anesthesia results in re-anesthetization. Anesth Analg 2014; 119:829-835.
47. Ingrande J, Brodsky JB, Lemmens HJ. Lean body weight scalar for the anesthetic induction dose of propofol in morbidly obese subjects. Anesth Analg 2011; 113:57-62.
48. Servin F, Farinotti R, Haberer JP, Desmonts JM. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study. Anesthesiology 1993; 78:657-665.
49. Cortnez LI, Anderson BJ, Penna A, et al. Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. Br J Anaesth 2010; 105:448-456.
50. van Kralingen S, Diepstraten J, Peeters MYM, et al. Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. Clin Pharmacokinet 2011; 50:739-750.
51. Eleveld DJ, Proost JH, Cortnez LI, et al. A general purpose pharmacokinetic model for propofol. Anesth Analg 2014; 118:1221-1237.
52. Cortnez LI, De La Fuente N, Eleveld DJ, et al. Performance of propofol targetcontrolled infusion models in the obese: pharmacokinetic and pharmacodynamic analysis. Anesth Analg 2014; 119:302-310.
53. Lehavi A, Sandler O, Mahajna A, et al. Comparison of rhabdomyolysis markers in patients undergoing bariatric surgery with propofol and inhalation-based anesthesia. Obes Surg 2015; 25:1923-1927.
54. Zoremba M, Dette F, Hunecke T, et al. A comparison of desflurane versus propofol: the effects on early postoperative lung function in overweight patients. Anesth Analg 2011; 113:63-69.
55. Lemmens HJM. Perioperative pharmacology in morbid obesity. Curr Opin Anaesthesiol 2010; 23:485-491.
56. Monk TG, Rietbergen H, Woo T, Fennema H. Use of sugammadex in patients with obesity: a pooled analysis. Am J Ther 2015. [Epub ahead of print]
57. Van Lancker P, Dillemans B, Bogaert T, et al. Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients. Anaesthesia 2011; 66:721-725.
58. Staehr-Rye AK, Rasmussen LS, Rosenberg J, et al. Surgical space conditions during low-pressure laparoscopic cholecystectomy with deep versus moderate neuromuscular blockade: a randomized clinical study. Anesth Analg 2014; 119:1084-1092.
59. Hoffmann U, Grosse-Sundrup M, Eikermann-Haerter K, et al. Calabadion: a new agent to reverse the effects of benzylisoquinoline and steroidal neuromuscular-blocking agents. Anesthesiology 2013; 119:317-325.
60. Curry JLA. Threshold monitoring, alarm fatigue, and the patterns of unexpected hospital death. APSF Newslett 2011; 26:32-35.
61. Porhomayon J, Leissner KB, El-Solh AA, Nader ND. Strategies in postoperative analgesia in the obese obstructive sleep apnea patient. Clin J Pain 2013; 29:998-1005.
62. Ingrande J, Lemmens HJM. Dose adjustment of anaesthetics in the morbidly obese. Br J Anaesth 2010; 105(Suppl):i16-i23.
63. Gregoire N, Hovsepian L, Gualano V, et al. Safety and pharmacokinetics of paracetamol following intravenous administration of 5 g during the first 24 h with a 2-g starting dose. Clin Pharmacol Ther 2007; 81:401-405.
64. Michaut A, Moreau C, Robin M-A, Fromenty B. Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease. Liver Int 2014; 34:e171-e179.
65. Alvarez A, Singh PM, Sinha AC. Postoperative analgesia in morbid obesity. Obes Surg 2014; 24:652-659.
66. Pickering G, Loriot M-A, Libert F, et al. Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism. Clin Pharmacol Ther 2006; 79:371-378.
67. Roberts E, Delgado Nunes V, Buckner S, et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis 2015. [Epub ahead of print]. doi:10.1136/annrheumdis-2014-206914.
68. Klein M, Støckel M, Rosenberg J, Gögenur I. Intra-operative ketorolac and bleeding after laparoscopic Roux-en-Y gastric by-pass surgery. Acta Chir Belg 2012; 112:369-373.
69. Hakkarainen TW, Steele SR, Bastaworous A, et al. Nonsteroidal anti-inflammatory drugs and the risk for anastomotic failure: a report from Washington State's Surgical Care and Outcomes Assessment Program (SCOAP). JAMA Surg 2015; 150:223-228.
70. Levin A, Klein SL, Brolin RE, Pitchford DE. Patient-controlled analgesia for morbidly obese patients: an effective modality if used correctly. Anesthesiology 1992; 76:857-858.
71. Waldron NH, Jones C, Gan TJ, et al. Impact of peri-operative dexamethasone on postoperative analgesia and side-effects: Systematic review and metaanalysis. Br J Anaesth 2013; 110:191-200.
72. De Oliveira GS, Duncan K, Fitzgerald P, et al. Systemic lidocaine to improve quality of recovery after laparoscopic bariatric surgery: a randomized doubleblinded placebo-controlled trial. Obes Surg 2014; 24:212-218.